Mr. Ranpariya and Dr. Kats are from Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey. Dr. Lipoff is from the Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Cutis. 2022 Apr;109(4):211-217. doi: 10.12788/cutis.0503.
The direct-to-consumer (DTC) telemedicine industry, including teledermatology, has seen rapid expansion in recent years, partly because of the COVID-19 pandemic. The shortage of dermatologists and the visual nature of dermatologic conditions attracted DTC companies to dermatology. As more patients continue to seek medical consultations and prescription medications from these for-profit companies, we must approach their growth with healthy skepticism. Shortcomings of DTC teledermatology include concerns about conflicts of interest (COIs), overdiagnosis, and overprescribing. Although DTC teledermatology is certainly here to stay, an appropriate understanding of this industry will allow dermatologists to advise patients and advocate for best practices.
近年来,直接面向消费者(DTC)的远程医疗行业,包括远程皮肤病学,得到了快速发展,部分原因是 COVID-19 大流行。皮肤科医生的短缺和皮肤病的直观性质吸引了 DTC 公司进入皮肤科领域。随着越来越多的患者继续从这些营利性公司寻求医疗咨询和处方药物,我们必须对它们的增长持健康怀疑的态度。DTC 远程皮肤病学的缺点包括对利益冲突(COI)、过度诊断和过度开药的担忧。虽然 DTC 远程皮肤病学肯定会继续存在,但对该行业的正确理解将使皮肤科医生能够为患者提供建议并倡导最佳实践。